Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1

Interventions

pembrolizumab 2fludarabine 2apatinib 2Interleukin-2 2Cyclophosphamide 2spartalizumab 1phosphorylethanolamine 1olaparib 1liposomal doxorubicin 1ivarmacitinib 1camrelizumab 1anlotinib 1Valproic Acid 1Topotecan 1Talc 1Pharmaceutical Services 1Injections 1Hydralazine 1Cisplatin 1Cerebral Decortication 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × ivarmacitinib × Other solid neoplasm × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡